Evidence vs access – addressing the balance in assessing new cancer drugs

A study in the BMJ last week has opened up a debate over the level of evidence needed before a drug is made available to patients. Here, our Science Information and Policy Officer, Dr Sam Dick, takes a look at the study in more detail.
Institute of Cancer Research